N4 Pharma Share Discussion Threads

[jakleeds] 19/1/2024 08:00

19 January 2024

N4 Pharma plc

("N4 Pharma" or the "Company")

Patent Grant

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to announce that the University of Queensland has informed the Company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec(R) in India.

The granted patent in India is for a composition of matter patent for the particle itself as well as the manufacturing process relating to how the particle is made and matches the patents granted in the USA, Canada, Europe, Japan, Australia and China .

Nigel Theobald, Chief Executive Officer of the Company, commented:

"The granting of this patent is a further indication of the strength of the intellectual property we have licensed from the University of Queensland and we now have all of the major global territories with granted patents for Nuvec(R)."

For more information please contact:

[barrie16] 18/1/2024 15:59

nobby

Do you know the principals at N4pharma personally?

[dplewis1] 16/1/2024 22:30

It's the same pillock who said in 2018 "Nuvec promises to become the industry standard, it's as simple as that." Nice one Dave, those human trials must be starting soon..

[nobbygnome] 16/1/2024 22:21

The ramping here has always been very amateurish and relies on someone swallowing the company’s spin lock stock and barrel. Fydo and his previous incarnations doesn’t understand the drug/device process to the clinic and the inherent risks involved. He has always been completely derailed by the facts as the projects fail one by one. I note he says about a toxicity study; they are always likely to throw up something unexpected. That’s the reality of science….which he is clearly clueless about!

[nobbygnome] 16/1/2024 22:09

LOL both projects are still preclinical! Nuff said….

[nobbygnome] 16/1/2024 21:26

So Fydo you are saying the company will be generating revenue by 16th December this year. Absolutely no chance….you are deluded…..or a ramper!

[dplewis1] 16/1/2024 16:09

You'll need a 20 bagger to break even by then Dave! Placing incoming..

[nobbygnome] 16/1/2024 15:53

Over many years this company has been shocking and essentially run for the benefit of the management. Lots of money spent and very little progress made!

[dplewis1] 16/1/2024 15:44

No one falls for it except Farrier .. yes of course the market is wrong and it definitely should have gone up on that.. when's Nigel passing the begging bowl round again??

[nobbygnome] 16/1/2024 15:37

So dplewis do you think it was an attempted P&D which went wrong because no-one falls for the company rubbish any more…

[nobbygnome] 16/1/2024 15:35

The point is it’s still a way off being in the clinic and absolutely miles from being a potential commercial entity. Lots more fund raises required before you get to the promised land….if you ever do!

[fydo] 16/1/2024 15:14

Such is the nature of trading on AIM that traders in their haste often misread an RNS which is what I think has happened today.
Traders have interpreted ECP-105 as being at the start of it's development as opposed to the reality of them preparing the refined formulation to take into clinic.
It is helpful to look back at the Nanogenics RNS to see where we are at this stage, ie, preparing the refined formulation for clinic.

"Nanogenics has already undertaken an initial proof of concept in-vivo study which has demonstrated that a single dose of ECP105 can match the anti-fibrotic effect of Mitomycin C but does not have the cytotoxic side effects, so unlike Mitomycin C, it can be dosed repeatedly. Nanogenics will use the proceeds received as part of the investment by the Company to repeat this study using a novel formulation containing its proprietary siRNA sequence as preparation for discussions with the FDA and MHRA to approve a GLP toxicity regulatory study and first in human clinical trials."
It is this refined formulation that will form the basis of discussions with the FDA and MHRA prior to a toxicity report and clinical trials.

[dplewis1] 16/1/2024 08:53

Market seeing through the waffle. Dave you've been had over by Nigel again.. how many times is that now..??

[dplewis1] 16/1/2024 08:14

Nobby, it's another Dave Farrier handle

[mrsqueezy] 16/1/2024 08:01

Nice update!

[nobbygnome] 16/1/2024 08:00

Preclinical studies!! Need I say more….

[fydo] 11/1/2024 11:33

To add to my previous posting, a couple of further observations regarding Nanogenics/Nuvec. Firstly people say that N4 only has one product and that it is years away from monitisation. This is only partially true because the investment in Nanogenics gives them both a product that is near to clinic,which even in its non refined state is better than anything on the market that addresses a clear and growing need, together with a string of other promising products. To quote from the Nanogenics website "Our lead product, ECP-105, is our novel glaucoma therapy. We expect to have it in clinic in 2025, followed closely by several other promising medicines." The Nanogenics investment therefore gives them plenty of options.
The other comment I would make is that Nuvec being a delivery system means that it has in the past been beholden to the drug developers to get Nuvec into clinic. The company have spoken before about bringing their own products to market and what the Nanogenics investment does is bring a drug developer together with a delivery system meaning that N4 are no longer beholden to third party drug developer timescales, indeed N4 have already stated that the next stage of Nuvecs development is to identify a clear product to take into clinic.
Nuvec could be used for Nanogenics drug development or Nanogenics could develop drugs for Nuvec. Either way it speeds up the timelines to get into clinic.

[nobbygnome] 08/1/2024 15:12

Hmmmm Fydo’s first post since October 2019 and as far as I can see he has never posted on N4P before. Who has tipped him the wink….

[fydo] 08/1/2024 11:26

Things are coming together here and the dots are being joined. One of the issues being discussed is funding. N4 have already stated that Nanogenics could be funded by third parties. To this end it is interesting that Dr Simon Newman the Chief Scientific officer of Nanogenics will take up the same role at the Brain Tumour Charity next month whilst continuing that role at Nanogenics. Interesting because the Brain Tumour Charity is both heavily involved in tumour research itself but more importantly is a major financier of tumour research both directly and through third parties. To have the Nanogenics CSO acting in the interests of Nanogenics/Nuvec could be very advantageous.

[nobbygnome] 08/1/2024 07:35

Insider trading?!? Hmmmm…

I thought it was funny that they referenced immunogenicity problems with the viral vector. They haven’t put the Nuvec particles into humans yet so have no idea if there will be any tolerability issues with their own product!

This project remains many years from monetisation….